Literature DB >> 27493614

The Role of CDK 4/6 Inhibitors in Breast Cancer Treatment.

Isabell Witzel1, Volkmar Müller1.   

Abstract

Entities:  

Year:  2016        PMID： 27493614      PMCID： PMC4960363          DOI： 10.1159/000447479

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN： 1661-3791            Impact factor:   2.860


× No keyword cloud information.
  9 in total

Review 1.  Aromatase inhibitors in breast cancer.

Authors:  Ian E Smith; Mitch Dowsett
Journal:  N Engl J Med       Date:  2003-06-12       Impact factor: 91.245

Review 2.  Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer.

Authors:  Romualdo Barroso-Sousa; Geoffrey I Shapiro; Sara M Tolaney
Journal:  Breast Care (Basel)       Date:  2016-06-22       Impact factor: 2.860

Review 3.  Palbociclib - from Bench to Bedside and Beyond.

Authors:  Marcus Schmidt
Journal:  Breast Care (Basel)       Date:  2016-06-22       Impact factor: 2.860

Review 4.  Palbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast Cancer.

Authors:  Johannes Ettl
Journal:  Breast Care (Basel)       Date:  2016-06-23       Impact factor: 2.860

5.  The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

Authors:  Richard S Finn; John P Crown; Istvan Lang; Katalin Boer; Igor M Bondarenko; Sergey O Kulyk; Johannes Ettl; Ravindranath Patel; Tamas Pinter; Marcus Schmidt; Yaroslav Shparyk; Anu R Thummala; Nataliya L Voytko; Camilla Fowst; Xin Huang; Sindy T Kim; Sophia Randolph; Dennis J Slamon
Journal:  Lancet Oncol       Date:  2014-12-16       Impact factor: 41.316

6.  The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer.

Authors:  Emily E Bosco; Ying Wang; Huan Xu; Jack T Zilfou; Karen E Knudsen; Bruce J Aronow; Scott W Lowe; Erik S Knudsen
Journal:  J Clin Invest       Date:  2006-12-07       Impact factor: 14.808

7.  Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.

Authors:  Massimo Cristofanilli; Nicholas C Turner; Igor Bondarenko; Jungsil Ro; Seock-Ah Im; Norikazu Masuda; Marco Colleoni; Angela DeMichele; Sherene Loi; Sunil Verma; Hiroji Iwata; Nadia Harbeck; Ke Zhang; Kathy Puyana Theall; Yuqiu Jiang; Cynthia Huang Bartlett; Maria Koehler; Dennis Slamon
Journal:  Lancet Oncol       Date:  2016-03-03       Impact factor: 41.316

8.  Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

Authors:  Stephen Chia; William Gradishar; Louis Mauriac; Jose Bines; Frederic Amant; Miriam Federico; Luis Fein; Gilles Romieu; Aman Buzdar; John F R Robertson; Adam Brufsky; Kurt Possinger; Pamela Rennie; Francisco Sapunar; Elizabeth Lowe; Martine Piccart
Journal:  J Clin Oncol       Date:  2008-03-03       Impact factor: 44.544

9.  Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial.

Authors:  N Harbeck; S Iyer; N Turner; M Cristofanilli; J Ro; F André; S Loi; S Verma; H Iwata; H Bhattacharyya; K Puyana Theall; C H Bartlett; S Loibl
Journal:  Ann Oncol       Date:  2016-03-30       Impact factor: 32.976
  9 in total
  2 in total

1.  Altered Expression of Cell Cycle Regulators in Adult T-Cell Leukemia/ Lymphoma Patients.

Authors:  Reza Torshizi; Ehsan Ghayour Karimani; Kobra Etminani; Mohammad Mehdi Akbarin; Khadijeh Jamialahmadi; Abbas Shirdel; Hossein Rahimi; Abolghasem Allahyari; Amin Golabpour; Houshang Rafatpanah
Journal:  Rep Biochem Mol Biol       Date:  2017-10

2.  Efficacy of a CDK4/6 Inhibitor in a Patient with Breast Cancer and Liposarcoma: A Case Report and Review of the Literature.

Authors:  Laura Loretan; Linda Eszter Moskovszky; Michael Kurrer; G Ulrich Exner; Andreas Trojan
Journal:  Breast Care (Basel)       Date:  2018-11-14       Impact factor: 2.860
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.